美凱龍AH齊漲 37億!紅星美凱龍定增獲眾多知名機構超額認購
格隆匯10月22日丨美凱龍(601828.SH)漲近7%,報10.2元;紅星美凱龍(01528.HK)亦漲約4%,報4.6港元。紅星美凱龍昨日披露了“非公開發行股票發行結果暨股本變動公吿”。公吿顯示,紅星美凱龍本次非公開發行股票的數量約為4.5億股,募集資金總額為人民幣37.01億元。公吿顯示,本次發行對象最終確定為17名,包括國泰君安、信達證券、睿遠基金、財通基金、諾德基金、法國巴黎銀行、阿里巴巴(成都)軟件技術有限公司等等,均為國內外知名機構,“全明星陣容”不僅展現公司廣受資本市場認可,同時也進一步實現了股東陣容和資金來源的多元化。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.